Skip to main content
3 Nutrients Affected · Based on CTD Molecular Database

What Does Atorvastatin Deplete? 3 Nutrients Affected

Atorvastatin (Lipitor) depletes coenzyme Q10, vitamin D, and vitamin K2 by blocking the mevalonate pathway that produces both cholesterol and these essential nutrients. The Comparative Toxicogenomics Database catalogs 340 gene interactions for atorvastatin, with 5,392 disease associations across approximately 30 million U.S. prescriptions annually. CoQ10 blood levels can drop 40-50% within weeks of starting statin therapy, explaining the muscle pain that 10-30% of users report.

Taking this medication? Check what it depletesFree, 10 seconds →

Data sourced from CTD, ChEMBL, FAERS, PubMed, PharmGKB. How we verify this data →
Sources verified as of April 2026
[01]

Depletions Overview

Coenzyme Q10

High

Atorvastatin inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in both cholesterol and CoQ10 synthesis through the shared mevalonate pathway. When you block cholesterol production, you simultaneously block CoQ10 production — they share the same biochemical assembly line. According to PharmGKB annotations, the COQ2 gene is directly linked to atorvastatin toxicity and muscular diseases, confirming the mechanistic connection between statin use, CoQ10 depletion, and muscle symptoms at the genetic level.

Onset: 2-4 weeks (blood levels decline rapidly)
Muscle pain and soreness that worsens with physical activityLeg cramps that wake you up at nightFatigue so heavy it feels like your body has no fuelWeakness climbing stairs or getting up from a chairJoint stiffness that started after beginning the medication

Vitamin D

Low-Moderate

Atorvastatin may impair the conversion of 25-OH vitamin D to its active form 1,25-dihydroxyvitamin D through effects on hepatic CYP enzyme systems. The drug's extensive first-pass metabolism in the liver, where vitamin D activation also occurs, creates competition for enzymatic processing. According to CTD data linking atorvastatin to 5,392 disease associations, metabolic pathway interactions extend beyond cholesterol to include fat-soluble vitamin processing, compounding risk in a population already prone to vitamin D insufficiency.

Onset: Months of regular use
Bone aches that develop gradually after starting the statinMuscle weakness that overlaps with and worsens CoQ10 depletion symptomsMood changes or seasonal depression worseningIncreased susceptibility to colds and respiratory infectionsFatigue layered on top of the CoQ10-driven energy deficit

Vitamin K2

Low

The mevalonate pathway blocked by atorvastatin also produces vitamin K2-dependent proteins, including matrix Gla protein (MGP) and osteocalcin, which direct calcium into bones and away from arterial walls. According to 340 gene interactions cataloged in CTD for atorvastatin, the enzyme pathway disruption extends to K2-dependent calcium metabolism. This creates a paradox where a drug prescribed to prevent cardiovascular disease may contribute to arterial calcification by reducing the K2-dependent protein that prevents it.

Onset: Months of regular use
No overt symptoms in early depletion — this is a silent riskArterial calcification progressing despite cholesterol reductionBone density declining over years of statin useBruising more easily than before starting the medicationDental health declining with weakening enamel

Wondering about YOUR specific medications?

Check free — no signup, 10 seconds →
[02]

How It Causes Depletions

Atorvastatin is an HMG-CoA reductase inhibitor prescribed to approximately 30 million Americans annually under the brand name Lipitor for high cholesterol, cardiovascular disease prevention, familial hypercholesterolemia, and post-heart attack or stroke protection. According to ChEMBL mechanism-of-action data, atorvastatin carries Phase 4 indications for hypercholesterolemia, dyslipidemias, myocardial infarction, heart failure, hypertension, stroke, and cardiovascular diseases. With oral bioavailability of only 14% due to extensive hepatic first-pass metabolism, peak plasma concentration of 28 ng/mL at 1.5 hours, 98% protein binding, and an elimination half-life of 14 hours, atorvastatin concentrates its activity primarily in the liver where cholesterol synthesis occurs. The drug's 380-liter volume of distribution indicates significant tissue penetration beyond the liver, explaining why muscle tissue CoQ10 levels decline alongside hepatic levels.

The Comparative Toxicogenomics Database catalogs 340 gene interactions for atorvastatin, with 5,392 total disease associations and 111 curated disease links — the broadest molecular footprint of any statin in the database. The mevalonate pathway that atorvastatin blocks is not exclusively a cholesterol production line — it is a branching metabolic superhighway that also produces CoQ10 (via the prenylation branch), vitamin K2-dependent activation of calcium-directing proteins, dolichol (needed for glycoprotein synthesis), and isoprenoids (essential for cell signaling). When HMG-CoA reductase is inhibited, all downstream products decline, not just cholesterol. CoQ10 depletion is the most clinically significant because CoQ10 serves as the essential electron carrier in mitochondrial complexes I through III, and heart muscle contains the highest CoQ10 concentration of any tissue at approximately 110 mcg per gram — meaning the organ this medication protects is also the organ most vulnerable to this depletion.

PharmGKB pharmacogenomic annotations include 10 entries for atorvastatin, with level 1A evidence — the highest classification — linking SLCO1B1 gene variants to drug metabolism, and a notable annotation linking the COQ2 gene directly to statin toxicity and muscular diseases. This COQ2 pharmacogenomic link confirms at the genetic level what patients experience clinically: statin-induced CoQ10 depletion causes muscle symptoms. Individuals with SLCO1B1 variants that increase hepatic atorvastatin uptake face higher drug exposure and potentially faster CoQ10 decline. Across 212 million rows in Kelda's database, the atorvastatin depletion pattern is distinctive because CoQ10 depletion begins within 2-4 weeks — faster than most medication-induced nutrient depletions — and the PharmGKB COQ2 annotation provides a pharmacogenomic roadmap for identifying which patients are genetically predisposed to the worst muscle side effects.

[03]

Symptoms to Watch For

Muscle pain and soreness that worsens with physical activityLeg cramps that wake you up at nightFatigue so heavy it feels like your body has no fuelWeakness climbing stairs or getting up from a chairJoint stiffness that started after beginning the medicationBone aches that develop gradually after starting the statinMuscle weakness that overlaps with and worsens CoQ10 depletion symptomsMood changes or seasonal depression worseningIncreased susceptibility to colds and respiratory infectionsFatigue layered on top of the CoQ10-driven energy deficitNo overt symptoms in early depletion — this is a silent riskArterial calcification progressing despite cholesterol reductionBone density declining over years of statin useBruising more easily than before starting the medicationDental health declining with weakening enamel

Atorvastatin-induced nutrient depletions create a layered symptom pattern where CoQ10 depletion hits first and hardest within weeks, vitamin D decline develops over months, and vitamin K2 effects accumulate silently over years. The muscle pain and fatigue from CoQ10 depletion are often the most visible symptoms, affecting 10-30% of statin users. But vitamin D and K2 depletions compound the picture, adding bone and cardiovascular risks that are harder to detect without targeted blood testing.

[04]

What to Monitor

Request these at your next appointment. Check the ones you want to remember.

[05]

What vs Others

NameDepletionsPotencyNotes
AtorvastatinThis drug3 nutrientsHighMost prescribed statin with 340 CTD gene interactions, high-intensity cholesterol reduction with 14h half-life
Rosuvastatin3 nutrientsHighMost potent per-milligram LDL reduction, hydrophilic with potentially less muscle penetration
Simvastatin3 nutrientsModerateLipophilic with higher muscle penetration, more drug interactions via CYP3A4
Pravastatin2 nutrientsLow-ModerateHydrophilic with least muscle penetration, fewer side effects but less potent cholesterol reduction

All statins block the mevalonate pathway and deplete CoQ10 through the same HMG-CoA reductase inhibition mechanism. Atorvastatin and rosuvastatin are high-intensity statins with the broadest depletion profiles. Pravastatin's hydrophilic structure means less muscle tissue penetration and one fewer depletion, but also less potent cholesterol reduction. According to CTD data, atorvastatin's 340 gene interactions represent the most extensively documented statin molecular footprint, with PharmGKB confirming COQ2 gene involvement in muscular toxicity.

[06]

Food Sources for Depleted Nutrients

FoodAmount per Serving
Beef heartHighest dietary CoQ10 source per serving
SardinesSignificant CoQ10 per 3.5oz serving
MackerelModerate-high CoQ10 per 3.5oz serving
Beef (grass-fed)Moderate CoQ10 per 3.5oz serving
PeanutsModerate CoQ10 per ounce

Source: USDA Food Composition Database (658,209 food nutrient entries)

[07]

FAQ

[08]

References

  1. [1]Comparative Toxicogenomics Database (CTD): 340 atorvastatin gene interactions, 5,392 disease associations, 111 curated disease links (accessed April 2026)
  2. [2]ChEMBL Database: Atorvastatin classified as HMG-CoA reductase inhibitor, Phase 4 indications for hypercholesterolemia, dyslipidemias, MI, heart failure, hypertension, stroke, and CVD (accessed April 2026)
  3. [3]PharmGKB Database: 10 pharmacogenomic annotations for atorvastatin including level 1A evidence for SLCO1B1 metabolism and COQ2 muscular toxicity link (accessed April 2026)
  4. [4]PubMed: Indexed articles for atorvastatin covering statin myopathy, hepatotoxicity, and cardiovascular outcomes (accessed April 2026)
  5. [5]FAERS Database: Adverse event reporting for atorvastatin including myalgia, rhabdomyolysis, and hepatic injury reports (accessed April 2026)
  6. [6]Kelda Health Intelligence Platform: Cross-referenced analysis across 212 million rows integrating CTD, ChEMBL, FAERS, PharmGKB, and PubMed datasets (accessed April 2026)
This information is generated from peer-reviewed molecular databases including the Comparative Toxicogenomics Database (CTD), ChEMBL, and indexed PubMed research. It is not medical advice. Always consult your healthcare provider before making changes to your medications or supplements. See our methodology →
Statin-Induced CoQ10 Depletion Guide
Complete pathway from statin use to muscle pain via CoQ10 depletion
Coenzyme Q10 Testing Guide
When and how to test CoQ10 levels in statin users
Statin Drug Class Overview
Compare nutrient depletion profiles across all statins

Check What YOUR Medications Deplete

Free. No signup. 10 seconds.

Check Now →